Hypothesis

Core claim: The activity level of the mechanistic target of rapamycin (mTOR) pathway is evolutionarily tuned to the extrinsic mortality risk of a species’ niche, establishing a physiological set‑point that determines the rate of senescence without being an adaptation for programmed death.

Mechanistic rationale

• mTOR drives anabolic growth and suppresses autophagy; high activity favors rapid reproduction but accelerates cellular damage [2]
• In environments with high extrinsic mortality (predation, disease), selection maximizes early‑life fecundity, favoring alleles that keep mTOR constitutively active [4]
• In low‑mortality niches, the fitness benefit of sustaining mTOR activity declines, allowing selection for modifiers that dampen mTOR signaling, thereby extending somatic maintenance [5]
• This view integrates antagonistic pleiotropy (early benefit, late cost) and mutation accumulation (variants affecting mTOR regulation accumulate when selection weakens) while rejecting the notion that aging itself is selected for [1]

Testable predictions

1. Comparative physiology: Species with low extrinsic mortality (naked mole‑rat, certain rockfish, giant tortoise) will exhibit lower basal mTORC1 activity in liver and muscle compared with high‑mortality counterparts (wild mouse, zebrafish) when matched for age and nutritional state.
2. Experimental manipulation: Pharmacologically raising mTORC1 activity in a low‑mortality species will shorten lifespan and increase age‑related pathology, whereas lowering mTORC1 in a high‑mortality species will not extend lifespan beyond wild‑type because other pathways (e.g., IGF‑1) compensate.
3. Genetic signature: Genome‑wide scans will reveal an excess of regulatory variants in mTOR pathway genes showing antagonistic pleiotropic effects (associated with early‑life reproductive metrics and late‑life mortality) across taxa, consistent with AP theory.
4. Plasticity test: Transplanting individuals from a high‑mortality environment to a low‑mortality laboratory setting will cause a down‑regulation of mTOR signaling over generations, accompanied by increased longevity, demonstrating an evolvable set‑point.

Methods to falsify

• Measure phospho‑S6K (a readout of mTORC1) in tissue biopsies from captive and wild populations of the same species; if no systematic difference correlates with extrinsic mortality, the hypothesis fails.
• Use rapamycin or CRISPR‑based activation of mTOR in naked mole‑rats; if lifespan is unchanged or extended, the causal link is refuted.
• Perform QTL mapping for longevity in outbred mouse populations derived from high‑predation islands; lack of enrichment for mTOR‑region loci would weaken the claim.

Implications

If supported, this framework reframes aging as a physiological side‑effect of a life‑history trade‑off rather than a programmed trait, directing longevity medicine toward modulating mTOR activity in a context‑aware fashion (e.g., intermittent inhibition matched to reproductive cycles) instead of attempting to override a presumed “death program.”